Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Additional milestone eligibility includes $75 million for successful technology transfer and $225 million for a qualifying U.S. launch.

Rhea-AI Summary

Novavax (Nasdaq: NVAX) earned a $125 million milestone payment as Sanofi initiated a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. The milestone was triggered by dosing the fifth patient. The trial assesses safety and immune responses in adults aged 60 and older, combining Novavax's Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose flu vaccine.

The partnership has generated over $1 billion in revenue for Novavax. Novavax is eligible for a $75 million milestone upon successful manufacturing technology transfer, anticipated in mid-2027, and $225 million upon a U.S. combination-vaccine launch after Sanofi completes U.S. clinical and regulatory requirements. The agreement also provides royalties on Sanofi's Nuvaxovid sales and combination products using Nuvaxovid, plus milestones and royalties for new Sanofi vaccines using Novavax's Matrix-M adjuvant.

6 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.$225 million additional milestone eligibility tied to a U.S. influenza-COVID-19 combination-vaccine launch. 13% of market cap
• Moderate point$125 million milestone earned after the fifth patient was dosed in Sanofi's Phase 3 combination-vaccine trial. 7.3% of market cap
• Moderate pointOver $1 billion in revenue generated for Novavax through the Sanofi partnership to date.
• Moderate point. Forward-looking: it has not happened yet and may not happen.$75 million milestone eligibility tied to manufacturing technology transfer, anticipated in mid-2027. 4.4% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Royalty eligibility covers Sanofi sales of Nuvaxovid and combination products using Nuvaxovid.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional milestones and royalties apply to new Sanofi vaccines using Novavax's Matrix-M adjuvant.

Negative

• Minor pointU.S. launch milestone requires Sanofi to complete all U.S. clinical and regulatory requirements successfully.
• Minor pointTechnology-transfer milestone remains conditional on successful completion of the manufacturing technology transfer.

Key Figures

Milestone payment earned: $125 million Manufacturing technology transfer milestone: $75 million U.S. launch milestone: $225 million +1 more

Milestone payment earned

$125 million

Earned upon initiation of Sanofi's Phase 3 trial, defined as the fifth patient dosed

Manufacturing technology transfer milestone

$75 million

Eligible upon successful completion, anticipated in mid-2027

U.S. launch milestone

$225 million

Eligible after a U.S. launch and successful completion of clinical and regulatory requirements

Partnership revenue to date

Over $1 billion

Revenue generated for Novavax through its Sanofi partnership

Key Terms

immunogenicity, adjuvant, milestone payment, royalties

4 terms

immunogenicity medical

"assessing the safety and immunogenicity of Nuvaxovid"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

adjuvant medical

"utilizing Novavax's Matrix-M® adjuvant"

An adjuvant is an ingredient added to a vaccine or other therapy to strengthen or shape the body’s response to the main active component, like a helper that makes the primary ingredient work better or longer. For investors, adjuvants matter because they can change how well a product performs, alter dosing and safety profiles, affect regulatory review, and therefore influence clinical success, market size and competitive advantage.

milestone payment financial

"has earned a $125 million milestone payment"

A milestone payment is a pre-agreed cash amount paid when a company reaches a specific, measurable achievement in a partnership, such as completing a clinical trial stage, receiving regulatory approval, or hitting a sales target. For investors it signals how future revenue and risk are shared — like progress payments on a construction project, these payments can unlock value and affect a company’s cash flow and valuation as each milestone is met.

royalties financial

"eligible to receive royalties on Sanofi sales"

Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease¹
• The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine
• Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone^® High-Dose vaccine in adults aged 60 and older.

"Novavax and Sanofi continue to successfully execute on the opportunities afforded by our partnership. To date, the partnership has generated over $1 billion in revenue for Novavax,"² said John C. Jacobs, President and Chief Executive Officer, Novavax. "Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and Novavax believes this is an important step toward that goal. We are excited about the value we are building together with our partners."

Under the collaboration and license agreement, for Nuvaxovid, Novavax is eligible to receive royalties on Sanofi sales and a $75 million milestone payment upon the successful completion of the manufacturing technology transfer anticipated in mid-2027. Novavax is also eligible to receive an additional milestone of $225 million upon a U.S. launch of an influenza-COVID-19 combination vaccine following successful completion by Sanofi of all clinical and regulatory requirements in the U.S. The agreement also includes royalties for any combination products developed by Sanofi using Nuvaxovid and milestones plus royalties for any new vaccines created by Sanofi utilizing Novavax's Matrix-M^® adjuvant.  

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient R&D innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, the possible achievement of additional milestones or receipt of milestone payments or royalties under the CLA, future marketing initiatives and the potential development and commercialization of Sanofi combination products, and efforts to pursue additional partnerships, are forward-looking statements. Additional clinical studies may be required to support regulatory filings in the U.S. market for the combined influenza-COVID-19 program. The U.S. may have different regulatory requirements from other markets. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges related to Novavax's partnership with Sanofi and in pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Sanofi to pursue planned regulatory pathways; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Naina Zaman
240-410-5353
ir@novavax.com

Media
Yvonne Sprow
240-720-7804
media@novavax.com

References

1. 2025 Flu and COVID-19 global market revenues based on revenue disclosures from the primary market participants in their SEC filings.
2. Novavax revenue recognized from upfront payments, milestones, R&D reimbursement and royalties through 6/30/2026 plus achievement of the $125 million CIC Phase 3 milestone in November 2026.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combination-vaccine-trial-in-europe-302923786.html

SOURCE Novavax, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What triggered Novavax's $125 million Sanofi milestone payment?

Novavax earned the $125 million milestone payment when the fifth patient was dosed in Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial in Europe. The trial evaluates Nuvaxovid combined with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults aged 60 and older.

What additional milestone payments can Novavax receive from Sanofi?

Novavax is eligible for $75 million upon successful manufacturing technology transfer, anticipated in mid-2027, and $225 million upon a U.S. influenza-COVID-19 combination-vaccine launch following Sanofi's successful completion of all U.S. clinical and regulatory requirements.